

TABLE OF CONTENTS

Book 5

Preface.....	i
Editorial Board.....	ii
Book 5 Panel.....	iii
Disclosure of Potential Conflicts of Interest.....	vi
Book 5 Post Test.....	vii
Continuing Education and Program	
Evaluation Instructions.....	vii
Role of ACCP.....	xi

Infectious Diseases I

HIV INFECTION: NEW AND CHALLENGING ISSUES FOR MANAGING A CHRONIC DISEASE	
Learning Objectives.....	1
Introduction.....	1
Drug Interactions.....	1
Ritonavir.....	1
Abbreviations in This Chapter.....	2
Non-nucleoside Reverse Transcriptase Inhibitors.....	2
Gastric Acid-Reducing Agents.....	2
Opioids.....	2
Anticonvulsants.....	4
Rifamycins.....	4
Phosphodiesterase Enzyme 5 Inhibitors.....	4
Herbal Therapies and Dietary Supplements.....	5
Anti-retroviral Therapy for	
Treatment-Experienced Patients.....	5
Enfuvirtide.....	6
Tipranavir.....	7
Darunavir.....	7
Maraviroc.....	7
Raltegravir.....	8
Etravirine.....	8
Cardiovascular Disease and HIV.....	8
Treatment.....	10
Hepatitis C Coinfection.....	11
Factors Affecting Treatment.....	11
Treatment.....	11

Conclusion.....	12
Annotated Bibliography.....	12
Self-Assessment Questions.....	17

UPPER RESPIRATORY TRACT INFECTIONS IN PRIMARY CARE

Learning Objectives.....	23
Introduction.....	23
Epidemiology.....	23
Current Practice.....	23
General Principles of Antibiotic Use.....	23
Abbreviations in This Chapter.....	24
Rhinosinusitis.....	24
Pathophysiology.....	24
Etiology.....	24
Diagnostic Considerations.....	24
Complications.....	24
Treatment.....	25
Antibiotic Therapy.....	25
Adjunctive Therapy.....	25
Pharyngitis.....	26
Diagnostic Considerations.....	26
Complications.....	27
Treatment.....	27
Antibiotic Therapy.....	27
Interventions to Decrease Transmission.....	27
Acute Bronchitis.....	28
Pathophysiology.....	28
Etiology.....	28
Diagnostic Considerations.....	28
Complications.....	28
Treatment.....	28
Antibiotic Therapy.....	28
Adjunctive Therapy.....	28
Pertussis.....	29
Otitis Media.....	29
Conclusion and Educational Opportunities.....	30
Annotated Bibliography.....	30
Self-Assessment Questions.....	33

COMMUNITY-ASSOCIATED METHICILLIN- RESISTANT *STAPHYLOCOCCUS AUREUS*

Learning Objectives.....	37
Introduction.....	37

Emergence of CA-MRSA.....	37
Abbreviations in This Chapter.....	38
Risk Factors for CA-MRSA.....	38
Molecular Comparison of CA-MRSA and HCA-MRSA.....	38
Clinical Presentation of CA-MRSA.....	39
Prevalence of CA-MRSA.....	39
Pharmacotherapy.....	39
Optimizing Outcomes.....	39
Non-pharmacological Treatment Approaches.....	41
Clinical Overview of Antimicrobials for CA-MRSA.....	41
Clindamycin.....	41
Daptomycin.....	41
Doxycycline and Minocycline.....	41
Linezolid.....	42
Quinupristin-Dalfopristin.....	42
Tigecycline.....	42
Trimethoprim/Sulfamethoxazole.....	42
Vancomycin.....	42
Treatment.....	43
Clinical Management and Treatment Plan for MRSA Infections in the Community.....	43
Empiric Management and Site of Care Decision for <i>S. aureus</i> Infections in the Community.....	43
Prevention of CA-MRSA.....	43
Eradication of CA-MRSA Colonization (Decolonization).....	45
Patient Education.....	45
Quality Assurance.....	45
Role of the Pharmacist.....	45
Conclusion.....	45
Annotated Bibliography.....	46
Self-Assessment Questions.....	51
UPDATE ON VACCINES AND VACCINE-PREVENTABLE DISEASES	
Learning Objectives.....	55
Introduction.....	55
Abbreviations in This Chapter.....	56
New Immunization Schedules.....	56
Childhood Immunization.....	56
Adolescent Immunization.....	56
Adult Immunization.....	56
New General Recommendations on Immunizations.....	59
New Vaccines.....	60
Rotavirus Vaccine.....	60
Tetanus, Diphtheria, and Acellular Pertussis Vaccine.....	61
Meningococcal Conjugate Vaccine.....	62
Zoster Vaccine.....	62
Human Papillomavirus Vaccine.....	63
Other Changes in Immunization Science.....	64
Plan for Keeping Up with Immunization Science.....	64
Conclusion.....	65
Annotated Bibliography.....	65
Self-Assessment Questions.....	69

Infectious Diseases II

INFECTIONS IN THE LONG-TERM CARE SETTING	
Learning Objectives.....	73
Introduction.....	73
Prevalence of Infections in the Long-term Care Setting.....	73
Potential for Underdiagnosis or Overdiagnosis of Infection.....	73
Abbreviations in This Chapter.....	74
Pathophysiology.....	74
Age-Related Immunosenescence.....	74
Atypical Disease Presentation.....	74
Challenges to Accurate Infection Diagnosis.....	74
Resident Access to Assessment by Health Professionals.....	74
Access to Diagnostic Testing.....	76
Findings That Support Infection Diagnosis.....	76
Fever.....	76
Complete Blood Cell Count.....	76
Urinary Tract Infections.....	76
Asymptomatic Bacteriuria.....	76
Symptomatic Infection.....	77
Respiratory Tract Infection.....	78
Differentiating Pneumonia from Noninfectious Respiratory Conditions.....	78
Clinical Signs Supporting Pneumonia Diagnosis.....	78
Skin and Soft Tissue Infection.....	79
Gastrointestinal Infection.....	80
Bacteremia.....	80
Selection of Appropriate Antibiotic Drug Therapy.....	80
Classification of Infection Etiology.....	80
Application of Principles of Age-Related Changes in Pharmacokinetics and Pharmacodynamics to Drug and Dosage Selection.....	81
Route of Therapy.....	81
Duration of Therapy.....	81
Role of the Pharmacist.....	83
Prospective and Retrospective Drug Therapy Intervention.....	83
Overcoming Potential Barriers to Optimal Pharmaceutical Care.....	84
Drug Regimen Review.....	84
Conclusion.....	85
Annotated Bibliography.....	85
Self-Assessment Questions.....	89
UPDATE ON THE TREATMENT OF ENDOCARDITIS	
Learning Objectives.....	93
Introduction.....	93
Pathophysiology.....	93
Bacterial Etiology.....	93
Resistance Issues.....	93
Endocarditis Versus Persistent Bacteremia.....	93
Abbreviations in This Chapter.....	94
Quality Patient Care.....	94
Pharmacotherapy.....	94
Treatment Plan.....	94
Therapeutic Goals/Outcomes.....	94
Bacteriologic.....	94

Symptom Resolution.....	94
Mortality.....	95
Guidelines.....	95
Treatment of Choice.....	95
Empiric Therapy.....	95
Native Valve Endocarditis.....	95
Streptococcal Endocarditis.....	95
Penicillin Susceptible.....	95
Penicillin Intermediate.....	96
Penicillin Resistant.....	96
Staphylococcal Endocarditis.....	96
Methicillin-Sensitive <i>S. aureus</i>	
Endocarditis.....	96
Methicillin-Resistant <i>S. aureus</i>	
Endocarditis.....	97
Prosthetic Valve Endocarditis.....	97
Streptococcal Endocarditis.....	97
Penicillin Susceptible.....	97
Penicillin Nonsusceptible.....	97
Staphylococcal Endocarditis.....	98
Enterococcal Endocarditis.....	98
Susceptible to Penicillin, Gentamicin,	
and Vancomycin.....	98
Resistant to Gentamicin.....	98
Resistant to Penicillin.....	98
Resistant to Penicillin,	
Aminoglycosides, and Vancomycin.....	99
HACEK Organisms.....	99
Fungal Endocarditis.....	99
Gram-negative Aerobes.....	99
Culture-Negative Endocarditis.....	99
Effectiveness.....	100
Monitoring.....	100
Outpatient Antibiotic Therapy.....	100
Conclusion.....	100
Annotated Bibliography.....	100
Self-Assessment Questions.....	105
 NOSOCOMIAL PNEUMONIA	
Learning Objectives.....	109
Introduction.....	109
Pathophysiology.....	109
Diagnosis.....	109
Clinical Diagnostic Strategy.....	109
Abbreviations in This Chapter.....	110
Bacteriologic Diagnostic Strategy.....	110
Treatment Goals.....	110
Quality Patient Care.....	111
Empiric Agents for Patients Without Risk	
Factors for Multidrug-Resistant Pathogens.....	111
Empiric Antimicrobial Agents for Patients	
at Risk of Multidrug-Resistant, Gram-Positive	
Pathogens (Specifically MRSA).....	112
Empiric Agents for Patients at Risk of	
Multidrug-Resistant, Gram-Negative	
Pathogens.....	115
Treatment Plan.....	119
Monitoring.....	119
Quality Improvement.....	119
Conclusion.....	120
Annotated Bibliography.....	120
Self-Assessment Questions.....	123